Research programme: acetylcholinesterase - Protalix Biotherapeutics

Drug Profile

Research programme: acetylcholinesterase - Protalix Biotherapeutics

Alternative Names: AChE programme - Protalix Biotherapeutics

Latest Information Update: 12 Mar 2012

Price : $50

At a glance

  • Originator Boyce Thompson Institute for Plant Research; Hebrew University of Jerusalem
  • Developer Protalix Biotherapeutics
  • Class Antitoxins; Recombinant proteins
  • Mechanism of Action Cholinesterase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Poisoning

Most Recent Events

  • 07 Mar 2012 No development reported - Preclinical for Poisoning in Israel (Parenteral)
  • 22 Jan 2008 Protalix Biotherapeutics extends its research agreement with Yissum Research Development Company to include a collaborative research programme at the Hebrew University of Jerusalem
  • 22 Jan 2008 Preclinical trials in Poisoning in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top